# Bioequivalence Study of Moksi® 400mg Tablet and Avelox® 400mg Tablet (Moxifloxacin) Under Fasting Condition in Healthy Adult Pakistani Subjects

> **NCT05307614** · PHASE1 · COMPLETED · sponsor: **Abbott** · enrollment: 38 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Moksi® 400mg Tablet
- **DRUG:** Drug: Avelox® 400Mg Tablet

## Key facts

- **NCT ID:** NCT05307614
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-27
- **Primary completion:** 2019-04-23
- **Final completion:** 2019-04-27
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05307614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05307614, "Bioequivalence Study of Moksi® 400mg Tablet and Avelox® 400mg Tablet (Moxifloxacin) Under Fasting Condition in Healthy Adult Pakistani Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05307614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*